{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:54Z","timestamp":1791994314241,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jbo.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T14:00:59Z","timestamp":1473775259000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries"],"prefix":"10.1016","volume":"5","author":[{"given":"Jean-Jacques","family":"Body","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves Pascal","family":"Acklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Finek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Sleeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2016.07.003_bib1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2016.07.003_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jbo.2016.07.003_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2014.08.022","article-title":"Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study","volume":"86","author":"Cetin","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-11-29","article-title":"Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark","volume":"11","author":"Jensen","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib5","first-page":"3279","article-title":"Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"21","author":"Oster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urolonc.2014.09.010","article-title":"The burden of skeletal-related events in patients with prostate cancer and bone metastasis","volume":"33","author":"Roghmann","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.eursup.2006.07.016","article-title":"New research findings on clinical benefits of bisphosphonates in patients with advanced prostate cancer","volume":"5","author":"Clarke","year":"2006","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.jbo.2016.07.003_bib8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib9","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib10","first-page":"879","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib12","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12094-013-1077-2","article-title":"Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours","volume":"16","author":"Duran","year":"2014","journal-title":"Clin. Transl. Oncol."},{"issue":"2014","key":"10.1016\/j.jbo.2016.07.003_bib14","first-page":"15","article-title":"Canadian health care institution resource utilization resulting from skeletal-related events","volume":"42","author":"Habib","year":"1995","journal-title":"Hosp. Pract."},{"key":"10.1016\/j.jbo.2016.07.003_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2016.07.003_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","article-title":"Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective \u2013 prospective observational study \u2013 a cohort from 4 European countries","volume":"3","author":"Hoefeler","year":"2014","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib17","first-page":"1","article-title":"Health resource utilization associated with skeletal-related events: results from a retrospective European study","author":"Body","year":"2015","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jbo.2016.07.003_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib19","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.jbo.2016.07.003_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2016.07.003_bib21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/07357907.2010.483508","article-title":"Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors","volume":"28","author":"Tchekmedyian","year":"2010","journal-title":"Cancer Investig"},{"key":"10.1016\/j.jbo.2016.07.003_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib24","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3111\/13696998.2013.774279","article-title":"The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium","volume":"16","author":"Body","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2016.07.003_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","article-title":"Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System","volume":"14","author":"Felix","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jbo.2016.07.003_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer. Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib29","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2016.07.003_bib30","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2016.07.003_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2016.07.003_bib33","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2016.07.003_bib35","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137416300240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137416300240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:47Z","timestamp":1761941747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137416300240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S2212137416300240"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2016.07.003","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}